norse: erdafitinib cetrelimab in muc with fgfr alterations
Published 2 years ago • 148 plays • Length 3:42Download video MP4
Download video MP3
Similar videos
-
2:20
erdafitinib /- cetrelimab in muc patients with fgfr alterations
-
2:34
norse: erdafitinib and cetrelimab in urothelial carcinoma
-
2:47
#esmo21 highlights on erdafitinib in adv. urothelial cancer with fgfra alterations: the norse study
-
1:04
thor: erdafitinib in advanced or metastatic urothelial cancer and fgfr alterations
-
1:47
thor: erdafitinib in metastatic urothelial cancer with fgfr alterations
-
5:14
erdafitinib demonstrates efficacy in intermediate-risk nmibc with fgfr alterations
-
3:26
blc2001: erdafitinib for muc
-
2:31
an update on erdafitinib for metastatic/uresectable fgfr alteration urothelial carcinoma
-
4:48
gefitinib approved for nsclc, atezolizumab shrinks bladder tumors, and more
-
3:41
the therapeutic potential of urolithin a for cancer treatment and prevention
-
4:47
asco 2023 highlights on erdafitinib in metastatic urothelial cancer with select fgfr alterations
-
6:09
erdafitinib (erda) or erda plus cetrelimab for patients with metastatic or locally advanced urot...
-
1:27
erdafitinib and enfortumab vedotin in pretreated fgfr2/3-mutant bladder cancer
-
1:48
urothelial neoplasm
-
3:25
enfortumab vedotin with pembrolizumab for bladder cancer
-
4:43
erdafitinib for fgfr-mutated urothelial carcinoma
-
0:34
pembrolizumab plus enfortumab vedotin for bladder cancer
-
1:49
blc2001: erdafitinib for the treatment of metastatic urothelial carcinoma
-
2:20
the role of erdafitinib in treating patients with bladder cancer
-
2:04
ibrutinib monotherapy in wm: long-term follow-up data
-
0:40
nadofaragene firadenovec shows durable responses in nmibc
-
3:46
perioperative management of advanced bladder cancer